CXCL8 and breast carcinoma: Our laboratory has revealed that miR-520b targeting HBXIP and IL-8 inhibits the migration of breast cancer cells[19], which is down-regulated in breast cancer cells and sensitizes breast cancer cells to complement attack[27].